The genetic disorder known as Alpha-1 Antitrypsin Deficiency (Alpha-1) is transmitted from parents to their offspring through their DNA. Genes are the instructions or coding that human body's cells follow to give us characteristics like blue eyes, black hair, etc. We say that our skin tone or another feature is inherited or genetic since we receive half of our genes from each parent when we are born. Alpha-1 lung disease is frequently referred to as ‘genetic COPD’ because it is genetic. Alpha-1 lung disease patients have two faulty genes (one from each parent). The Z and S genes are the most prevalent aberrant genes. The initial diagnosis of alpha-1 frequently includes asthma or COPD brought on by smoking (COPD). Emphysema and chronic bronchitis are both aspects of COPD. The most frequent genetic risk factor for COPD is alpha-1. Alpha-1 may be present in up to 3% of individuals with COPD who have not been tested.
Global genetic chronic obstructive pulmonary disease (COPD) market is estimated to be valued at US$ 560.3 million in 2022 and is expected to exhibit a CAGR of 3.2% during the forecast period (2022-2030).
Figure 1. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market Share (%), by Distribution Channel, 2022
Genetic Chronic Obstructive Pulmonary Disease (COPD) Market: Drivers
Increasing prevalence of chronic obstructive pulmonary disease (COPD), associated with awareness efforts carried out by individual organizations is expected to drive the global genetic chronic obstructive pulmonary disease (COPD) market growth over the forecast period.
Increasing prevalence of chronic obstructive pulmonary disease is expected to drive the global genetic chronic obstructive pulmonary disease (COPD) market growth over the forecast period. For instance, according to fact sheet published by World Health Organization in May 2022, Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Moreover, in November 2021, according to the data published by the National Heart, Lung and Blood Institute, each November, the chronic obstructive pulmonary disease (COPD) community comes together to promote better understanding of chronic obstructive pulmonary disease (COPD), a progressive lung disease that affects a lot of people across the U.S. Increasing awareness about chronic obstructive pulmonary disease (COPD) and its symptoms is important because early diagnosis and treatment can improve quality of life.
Figure 2.Global genetic chronic obstructive pulmonary disease (COPD) Market Share (%), by Region, 2022
Increasing research and development activities and product launches for treatment of chronic obstructive pulmonary disease are expected to drive the global genetic chronic obstructive pulmonary disease (COPD) market growth.
Increasing research and development activities by key players in market for the development of awareness and product launches is expected to drive the global genetic chronic obstructive pulmonary disease market growth. For instance, in June 2022, Verona Pharma, a pharmaceutical company, announced completion of the patient enrolment, with more than 800 subjects involved for its randomized ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. It is a critical step for the phase III ENHANCE trial with top-line data expected by the end of the year 2022 and further data from ENHANCE-2 in the third quarter of 2022.
Moreover, Verona Pharma, a pharmaceutical company, in May 2019, commenced a phase IIb clinical trial to assess nebulized ensifentrine (RPL554), in combination with a long-acting bronchodilator to treat moderate to severe chronic obstructive pulmonary disease.
Global genetic chronic obstructive pulmonary disease (COPD) Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
However, the COVID-19 pandemic had a positive impact on the global genetic chronic obstructive pulmonary disease (COPD) market, owing to the increasing demand of drugs used in the treatment of chronic obstructive pulmonary disease in patients infected with COVID-19 infection. For instance, according to an article published by the National Center for Biotechnology Information, providing access to biomedical and genomic information, in February 2022, chronic respiratory diseases (CRDs) affect the airways and other structures of the lungs, same dysfunction in lungs is observed in the patients infected with the coronavirus. The patients that are infected with coronavirus basically suffer from similar symptoms like breathing difficulty, insufficient supply of oxygen rich blood to lungs and overall body as in chronic obstructive pulmonary disease. Demand for drugs used in the treatment of chronic obstructive pulmonary disease increased as earlier in first wave of COVID-19 there was no particular drug therapy for treatment of COVID-19. The drugs used in treatment of chronic obstructive pulmonary disease were initially used in the treatment of coronavirus.
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2021 | Market Size in 2022: | US$ 560.3 Mn |
Historical Data for: | 2017 to 2020 | Forecast Period: | 2023 to 2030 |
Forecast Period 2023 to 2030 CAGR: | 3.2% | 2030 Value Projection: | US$ 720.5 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
GSK Plc, AstraZeneca Plc, Merck (Sigma-Aldrich), Dey Pharma, Grifols, S.A., Teva Pharmaceutical Industries Ltd, Baxter, Boehringer Ingelheim International GmbH, Kamada Ltd, Takeda Pharmaceutical Company Limited, LFB SA, Abeona Therapeutics, Alnylam Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Kedrion S.p.A., and Arrowhead Pharmaceuticals, Inc. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market: Key Developments
In May 2022, Alembic Pharmaceuticals Ltd, a pharmaceutical company, received final approval from the U.S. health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the U.S. Food & Drug Administration (U.S. FDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial.
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market: Restraint
The major factors that hinder growth of the global genetic chronic obstructive pulmonary disease (COPD) market include that the development of new drugs is a challenging task and drug failures (termination) in clinical trials. For instance, asthma drug benralizumab failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD, in May 2019. The Phase III, randomized, double-blind, placebo-controlled, parallel-group clinical trials GALATHEA and TERRANOVA evaluated the efficacy and safety of benralizumab for the prevention of exacerbations in patients with moderate to very severe COPD.
Key Players
Major players operating in the global genetic chronic obstructive pulmonary disease (COPD) market include GSK Plc, AstraZeneca Plc, Merck (Sigma-Aldrich), Dey Pharma, Grifols, S.A., Teva Pharmaceutical Industries Ltd, Baxter, Boehringer Ingelheim International GmbH, Kamada Ltd, Takeda Pharmaceutical Company Limited, LFB SA, Abeona Therapeutics, Alnylam Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Kedrion S.p.A., and Arrowhead Pharmaceuticals, Inc.
Alpha-1 deficiency-related emphysema is called as genetic Chronic obstructive pulmonary disease (COPD) involves lung inflammation, causing obstruction of airflow from the lungs. It is a chronic illness, and some of its symptoms include wheezing, mucus production, and breathing difficulties. Chronic bronchitis, emphysema, and refractory asthma are all symptoms of COPD, a degenerative lung condition. Chronic obstructive pulmonary disease (COPD) is mostly brought on by smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (a rare form of COPD), and other factors.
Each year, millions of people are affected by chronic obstructive pulmonary disease, or COPD for short. Emphysema and chronic bronchitis are two conditions that are collectively referred to as COPD. The lungs' alveoli, which are air sacs, suffer damage in emphysema. Breathlessness while exercising is the first sign of emphysema. Later, breathing difficulties can also happen while at rest. The four stages of chronic obstructive pulmonary disease (COPD) range from mild to very severe. Some symptoms may include an ongoing cough, shortness of breath, and wheezing.
Market Dynamics
Increasing adoption of organic strategies by key players in market such as product launch and approval is expected to drive market growth over the forecast period. For instance, in September 2020, GSK, Plc.,a pharmaceutical company and Innoviva Inc., a healthcare focused asset management company, announced that the U.S. Food and Drug Administration (FDA) approved a new indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients 18 years and older, expanding the current approval for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for the relief of acute bronchospasm. Moreover, several prospective drugs, primarily for COPD, are in the pipeline for respiratory illnesses, which is anticipated to boost growth of the global genetic chornic obstructive pulmonary disease (COPD) market.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients